This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study conducted in the United States (US) to assess the efficacy of RP-G28 compared to placebo on symptom reduction related to lactose intolerance.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
557
Change from baseline of the Lactose Intolerance (LI) symptom composite score compared to placebo
Change from baseline of the LI symptom composite score compared to placebo. The LI symptom composite score includes abdominal pain, abdominal bloating, abdominal cramping, and abdominal gas.
Time frame: Day 61
Proportion of patients with a meaningful reduction in LI composite score.
Proportion of patients with a meaningful reduction in LI composite score. The LI symptom composite score includes abdominal pain, abdominal bloating, abdominal cramping, and abdominal gas.
Time frame: Day 61
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Research Facility
Birmingham, Alabama, United States
Research Site
Chula Vista, California, United States
Research Site
Huntington Park, California, United States
Research Site
Lincoln, California, United States
Research Site
Los Angeles, California, United States
Research Site
Panorama City, California, United States
Research Site
San Diego, California, United States
Research Site
San Diego, California, United States
Research Site
Walnut Creek, California, United States
Research Site
Colorado Springs, Colorado, United States
...and 25 more locations